The changing shape of menopausal hormone therapy

Balan V.E.; Tikhomirova E.V.; Zaidieva Ya.Z.; Kruchinina E.V.; Zhuravel’ A.S.; Titchenko Yu.P.; Fomina-Nilova O.S.; Tsar’kova A.V.

doi:https://doi.org/10.17116/rosakush20202004195

Balan V.E.

Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-2364-6838

Tikhomirova E.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Kruchinina E.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Zhuravel’ A.S.

Moscow Regional Research Institute of Obstetrics and Gynecology

Titchenko Yu.P.

Moscow Regional Research Institute of Obstetrics and Gynecology

Fomina-Nilova O.S.

Moscow Regional Research Institute of Obstetrics and Gynecology

Tsar’kova A.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

The changing shape of menopausal hormone therapy

Authors:

Balan V.E., Tikhomirova E.V., Zaidieva Ya.Z., Kruchinina E.V., Zhuravel’ A.S., Titchenko Yu.P., Fomina-Nilova O.S., Tsar’kova A.V.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2020;20(4): 95‑99

DOI: 10.17116/rosakush20202004195

Read: 1709 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Balan VE, Tikhomirova EV, Zaidieva YaZ, et al. . The changing shape of menopausal hormone therapy. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(4):95‑99. (In Russ.)
https://doi.org/10.17116/rosakush20202004195

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Evaluation of the effectiveness of hormone therapy in patients with premature ovarian insufficiency. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):86-93

Depressive disorders in women during the menopausal transition and menopause. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):41-46

Carbonyl stress in menopausal women with insomnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):192-197

Awareness of women about the prevention and correction of climacteric disorders. Russian Journal of Preventive Medicine. 2025;(1):57-62

Assessment of the effect of menopause symptoms on women’s quality of life and their attitude to the manifestations of menopause and menopausal hormone therapy. Russian Journal of Human Reproduction. 2025;(3):84-91

Abstract:

The article presents the results of recent studies on the effectiveness, safety and duration of menopausal hormone therapy. Presented modern data on the indications and benefits of low and ultra-low doses of menopausal hormone therapy.

Keywords:

menopausal hormone therapy

low and ultra-low doses of estrogens

menopause

menopausal hormone therapy

low and ultra-low doses of estrogens

menopause

Authors:

Balan V.E.

Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-2364-6838

Tikhomirova E.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Kruchinina E.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Zhuravel’ A.S.

Moscow Regional Research Institute of Obstetrics and Gynecology

Titchenko Yu.P.

Moscow Regional Research Institute of Obstetrics and Gynecology

Fomina-Nilova O.S.

Moscow Regional Research Institute of Obstetrics and Gynecology

Tsar’kova A.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Received:

21.03.2020

Accepted:

17.04.2020

Close metadata

References:

Smetnik VP. From the chief editor. Menopause. 2011;2:3-53. (In Russ.).
Smetnik VP, Balan VE, Zaydieva YZ, Maychuk EYu, Mychka VB. Management of women with cardiovascular risk in peri- and postmenopausal women. Rossiiskii kardiologicheskii zhurnal. 2008;4:40-57. (In Russ.).
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19:257-271.
World population projected to reach 9.6 billion by 2050 with most growth in developing regions, especially Africa — say 21 June 2017, New York. https://www.un.org/development/desa/en/news/population/world-population-prospects-2017.html
Nachtigall LE, Nachtigall MJ. The perimenopause and vasomotor symptoms. Posgraduate Medicine, A special report. P. 5-7. https://doi.org/10.1016/S1086-5802(16)31127-5
Raus K. Conference Proceedings «Pres 2011 — Gynecology and Urology. Phytoneering research and experience summit». Mallorca. 2011. https://www.researchgate.net/topic/Phytotherapy/publications
The North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012;19:257.
Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC. The Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition [published online ahead of print February 16, 2015].
Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years [published online ahead of print February 20, 2015]. Menopause. 2015;22:7:694-701. https://doi.org/10.1097/gme.0000000000000383
Kaunitz AM, Manson JE. EDITORIAL. Failure to treat menopausal symptoms: a disconnect between clinical practice and scientific data. Menopause. 2015;22:7: https://doi.org/10.1097/gme.0000000000000457
Schneider HPG. The view of the International Menopause Society on The WHI. Climacteric. 2002;5:3:211-216.
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310:1353-1368.
Stefanick ML. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative Randomized Trials. JAMA. 2013; 310:1353-1368.
Kaunitz AM. Hormone therapy and breast cancer risk: trumping fear with facts. Menopause. 2006;13:160-163.
Smith GC, Wood AM, White IR, Pell JP, Hattie J. Birth weight and the risk of cardiovascular disease in the maternal grandparents. Am J Epidemiol. 2010;171:736-744.
de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, Davis SR, Gompel AA, Henderson VW, Langer R, Lobo RA, Plu-Bureau G, Sturdee, DW. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316-337.
de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees, M. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric. 2013;16:203-204.
ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123:202-216.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial et al. JAMA. 2002;288:321-333.
Ettinger B, Wang SM, Leslie RS, Patel BV, Boulware MJ, Mann ME, McBride M. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2012;19:6:610-615.